7 completed, 3 unknown, 1 active not recruiting, 1 terminated. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Unknown 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow Graft-versus-host-disease: new trials by email Literature Review of Graft-versus-host-disease trials Research Report on Graft-versus-host-disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Letermovir - Graft-versus-host-disease, CMV | Phase 2 | Unknown | Rabin Medical Center | 42 | 2023-10-01 | 2023-08-01 |
| A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. Cytarabine, Busulfan, Cyclophosphamide - Leukemia, Graft-versus-host-disease | Phase 2 | Unknown | Yi Luo | 46 | 2020-12-03 | 2023-02-21 |
| PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Ruxolitinib, Tacrolimus, Mycophenolate Mofetil - Graft-versus-host-disease, Stem Cell Transplant Complications | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 128 | 2020-11-03 | 2025-07-04 |
| HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis Treatment Arm - high dose ATG, Control Arm - standard of care - Graft-versus-host-disease, Relapse | Phase 2 | Terminated | AHS Cancer Control Alberta | 68 | 2020-07-01 | 2025-07-18 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation RGI-2001, Standard of Care - Graft Vs Host Disease, Graft-versus-host-disease | Phase 2 | Completed | Regimmune Corporation | 49 | 2019-11-25 | 2024-05-28 |
| Itacitinib for Low Risk GVHD Itacitinib - Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease | Phase 2 | Completed | John Levine | 70 | 2019-03-25 | 2023-02-06 |
| A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Alpha 1-Antitrypsin - Graft-versus-host-disease, GVHD | Phase 2 | Completed | John Levine | 30 | 2018-08-17 | 2021-07-12 |
| Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease CAM-101 10%, Vehicle Control, CAM-101 30% - Dry Eye, Graft-versus-host-disease | Phase 1 / Phase 2 | Completed | Cambium Bio Limited | 64 | 2018-05-01 | 2026-06-12 |
| Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT ATG - Graft-versus-host-disease, Prophylaxis | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 100 | 2017-05-30 | 2019-04-16 |
| In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis IL-2, Tacrolimus, Sirolimus - Graft-Versus-Host-Disease | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2014-03-25 | 2017-07-02 |
| Treatment of Steroid Resistant GVHD by Infusion MSC MSC (hPPL) - Graft-versus-host-disease | Phase 1 / Phase 2 | Completed | N.M. Wulffraat | 50 | 2009-01-01 | 2014-11-06 |
Graft vs Host Disease (12) · Blast Crisis (1) · Dry Eye Syndromes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Immune System Diseases (12) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Disease Attributes (2) · Hematologic Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bone Marrow Diseases (1) · Carcinogenesis (1)
Mycophenolic Acid (3) · Tacrolimus (3) · Cyclophosphamide (2) · Cyclosporine (2) · Blood Specimen Collection (1) · Busulfan (1) · Cytarabine (1) · Interleukin-2 (1) · KRN 7000 (1) · Methotrexate (1) · Semustine (1) · Sirolimus (1) · Standard of Care (1) · Vorinostat (1) · aldesleukin (1)
John Levine (2) · AHS Cancer Control Alberta (1) · Cambium Bio Limited (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · N.M. Wulffraat (1) · Rabin Medical Center (1) · Regimmune Corporation (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · St. Petersburg State Pavlov Medical University (1) · University of Michigan Rogel Cancer Center (1) · Yi Luo (1)
United States (6) · China (2) · Canada (1) · Netherlands (1) · Russia (1)
Brian Betts, MD (1) · Edmund K Waller, MD PhD (1) · Jan Storek, MD (1) · John Levine, MD (1) · John Levine, MD, MS (1) · Jurgen H Kuball, MD (1) · Moshe Yeshurun, MD (1) · Nico M Wulffraat (1) · Sung W Choi, MD, MS (1) · Yi Luo (1) · Yi-Bin Chen, MD (1)
PMID 28104702, PMID 33351103, PMID 36095841, PMID 40680268, PMID 42066960, PMID 42784255
P01CA039542 (1), UL1TR002240 (1)